Cystatin C levels in patients with β-thalassemia during deferasirox treatment
Ioannis Papassotiriou(National and Kapodistrian University of Athens), Antonis Kattamis, A. Sergounioti(Children's Hospital Agia Sophia), Evgenios Goussetis(Boston Children's Hospital), Eugenia Hantzi(Children's Hospital Agia Sophia), Polyxeni Delaporta(National and Kapodistrian University of Athens), Vassilios Ladis, Alexandra Margeli(National and Kapodistrian University of Athens)
Cited by 25
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Oxidative stress biomarkers responses to physical overtraining: Implications for diagnosis
|Free Radical Biology and Medicine|2007|305
Muscle damage, inflammatory, immune and performance responses to three football games in 1 week in competitive male players
|European Journal of Applied Physiology|2015|212
Sampling Time is Crucial for Measurement of Aerobic Exercise-Induced Oxidative Stress
|Medicine & Science in Sports & Exercise|2007|204
Physiological and performance adaptations of elite Greco-Roman wrestlers during a one-day tournament
|European Journal of Applied Physiology|2010|184